SynthesisEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Comparison of the efficacy of different pharmacological treatments for laryngopharyngeal reflux: a systematic review and network meta-analysis.
Synthesis in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveLaryngopharyngeal reflux (LPR) is a common disease, and various medications are employed clinically for its management, with variable efficacy. Therefore, this study aimed to assess the efficacy of different pharmacological treatments for LPR, thereby providing evidence-based guidance for its treatment.
methodsEmbase, Web of Science, Cochrane Library, and PubMed were comprehensively searched from inception to July 31, 2025, for studies on LPR. Two reviewers independently reviewed full texts and appraised the quality of eligible studies using the RoB 2.0 tool and the Newcastle-Ottawa Scale. R version 4.5.1 was employed to analyze data.
resultsIn total, 23 studies involving 1,958 individuals were included. The reflux symptom index (RSI) and reflux finding score (RFS) of these participants were analyzed at weeks 4, 8, and 12, respectively. According to league table results, for the RSI at week 4, compared with placebo, alginate yielded a weighted mean difference (WMD) of - 4.69 (95% credible interval [CrI]: - 8.97, - 0.28). For the RSI at week 8, compared with placebo, alginate yielded a WMD of - 6.27 (95% CrI: - 10.13, - 2.19). For the RSI at week 12, compared with placebo, proton pump inhibitors (PPIs) plus mucolytics yielded a WMD of - 9.75 (95% CrI: - 17.76, - 1.63). For the RFS at week 4, compared with potassium-competitive acid blockers (P-CABs), PPIs, and placebo, alginate yielded WMDs of - 3.55 (95% CrI: - 5.28, - 1.79), - 3.53 (95% CrI: - 4.83, - 1.90), and - 3.75 (95% CrI: - 4.87, - 2.56), respectively. For the RFS at week 8, compared with placebo, alginate yielded a WMD of - 4.12 (95% CrI: - 7.88, - 0.53). For the RFS at week 12, compared with placebo, alginate yielded a WMD of - 5.66 (95% CrI: - 10.25, - 1.14). According to the surface under the cumulative ranking curve (SUCRA), for the RSI at week 4, alginate ranked first (89.66%) and P-CABs ranked third (62.82%). For the RSI at week 8, alginate ranked first (84.50%). For the RSI at week 12, PPIs plus mucolytics ranked first (87.47%) and alginate ranked second (63.67%). For the RFS at week 4, alginate ranked first (99.43%). For the RFS at week 8, alginate remained the top-ranked treatment (88.30%). For the RFS at week 12, alginate ranked first (89.87%) and P-CABs ranked third (50.69%).
conclusionThis study revealed that alginate demonstrated the greatest efficacy in the treatment of LPR.
Indexed as
Identifiers
42223616What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.